China And Taiwan Move Toward Clinical Data Mutual Acceptance, Regulatory Harmonization
This article was originally published in PharmAsia News
Executive Summary
China and Taiwan's top health regulators have signed an agreement to harmonize clinical and non-clinical studies toward mutual data acceptance. The deal could open doors for more Taiwanese drugs in the Chinese market, industry experts say